MicroRNAs as lung cancer biomarkers

Table 3 Circulating miRNAs as biomarkers in lung cancer

MiRNA	Function	Scope	Sample	Ref.
miR-155, miR-197, miR-182 (UP)	Diagnostic	Lung cancer patients vs healthy controls	Plasma	[126]
miR-21, miR-210, miR-126, miR-486-5p (relative expression)	Diagnostic	NSCLC patients vs healthy controls	Plasma	[127]
miR-21–5p (UP) and miR-335–3p (DOWN)	Diagnostic	Lung cancer patients vs healthy controls	Plasma	[128]
miR-21, miR-155 (UP), miR-145 (DOWN)	Diagnostic	Lung cancer patient vs healthy smokers	Plasma	[129]
miR-361-3p, miR-625* (DOWN)	Diagnostic	Lung cancer patients vs healthy controls	Serum	[130]
miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a (DOWN), miR-29c (UP)	Diagnostic	Early stage NCSLC vs healthy controls	Serum	[131]
miR-92a, miR-484, miR-486-5p, miR-328, miR-191, miR-376a, miR-342, miR-331-3p, miR-30c, miR-28-5p, miR-98, miR-17-5p, miR-26b, miR-374, miR-30b, miR-26a, miR-142-3p, miR-103, miR-126, let-7a, let-7d, let-7b, miR-22, miR-148b, miR-139 (DOWN), miR-32, miR-133b, miR-566, miR-432-3p, miR-223, miR-29a, miR-148a, miR-142-5p, miR-140-5p (UP)	Diagnostic	Asymptomatic NSCLC patients vs healthy smokers	Serum	[132]
miR-205-5p, miR-205-3p, and miR-21-3p (UP)	Diagnostic	NSCLC patients vs benign lung disease and healthy controls	Serum	[133]
miR-190b, miR-630, miR-942 and miR-1284 (relative expression)	Diagnostic	Lung cancer patients vs healthy controls	Whole-blood	[85]
miR-22, miR-24, and miR-34a (UP)	Diagnostic	NSCLC patients vs healthy controls	Whole-blood	[134]
miR-205, miR-19a, miR-19b, miR-30b, miR-20a (DOWN)	Diagnostic	Patients after lung cancer surgery vs healthy controls	Plasma	[135]
miR-7, miR-21, miR-200b, miR-210, miR-219-1, miR-324 (UP), miR-126, miR-451, miR-30a, miR-486 (DOWN)	Diagnostic	NSCLC patients vs healthy controls	Plasma	[137]
miR-101, miR-106a miR-126, miR-133a, miR-140-3p, miR-140-5p, miR-142-3p, miR-145, miR-148a, miR-15b, miR-16, miR-17, miR-197, miR-19b, miR-21, miR-221, miR-28-3p, miR-30b, miR-30c, miR-320, miR-451, miR-486-5p, miR-660, and miR-92a (relative expression)	Diagnostic	NSCLC patients vs healthy controls	Plasma	[138]
miR-155, miR-197 (UP)	Prognostic	Lung cancer patients with metastasis vs patients without metastasis	Plasma	[126]
miR-486, miR-30d, miR-1, miR-499 (relative expression)	Prognostic	NSCLC patients vs healthy controls	Serum	[139]
let-7f, miR-30e-3p (DOWN)	Prognostic	NSCLC patients vs healthy controls	Plasma	[140]
miR-125b (relative expression)	Prognostic	NSCLC patients vs healthy controls	Serum	[141]
miR-21 (UP)	Response to treatment	Platinum chemotherapy-resistant patients vs non resistant patients	Plasma	[90]
miR-21 and miR-10b (UP)	Response to treatment	NSCLC patients with EGFR mutation vs patients without mutation	Plasma	[142]
miR-22 (UP)	Response to treatment	NSCLC patients vs healthy controls	Whole-blood	[134]

NSCLC: Non-small cell lung cancer.